Skip to content
drillr.ai

EWTX

Edgewise Therapeutics, Inc.

NASDAQ · USHealthcareBiotechnology
$38.81-2.39%

Price as of Jul 20, 2026

EWTX news

Edgewise Therapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business

    Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business PR Newswire SURESNES, France, July 13, 2026 * Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies.   * The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical needs.   SURESNES, France, July 13, 2026 /PRNewswire/ -- Servier, an inde

    PR Newswire ·

  2. Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

    Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules PR Newswire BOULDER, Colo., July 1, 2026 BOULDER, Colo., July 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on June 30, 2026, Edgewise granted inducement stock options to purchase a total of 16,50

    PR Newswire ·

  3. Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)

    Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) PR Newswire BOULDER, Colo., June 16, 2026 – No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers, symptoms and functional status across obstructive and nonobstructive HCM – – EDG

    PR Newswire ·

  4. Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business

    Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business PR Newswire SURESNES, France, June 1, 2026 * Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs. * Transaction includes sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. * Transaction represents total value of up to $2.65 billion. SURESNES, France, June 1, 2026 /PRNewswire/ -- Servier, an independent international pharm

    PR Newswire ·

  5. Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

    Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline PR Newswire BOULDER, Colo., June 1, 2026 — Edgewise to Receive $1.55 Billion in Upfront Cash Consideration and is Eligible to Receive up to $1.1 Billion in Regulatory and Commercial Milestones — — Transaction Creates Focused Cardiovascular Company with Enhanced Strategic Clarity — — Upfront Proceeds Expected to Fully Fund EDG-7500 Dev

    PR Newswire ·

  6. Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026

    Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026 PR Newswire BOULDER, Colo., May 12, 2026 BOULDER, Colo., May 12, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Edgewise leadership will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2026, at 10:00 am ET. (https://mma.prnewswire.com/media/2646316/Edgewise_Ther

    PR Newswire ·

  7. Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

    For best results when printing this announcement, please click on link below: https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260226:nPn4QbXrwa&default-theme=true Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs PR Newswire BOULDER, Colo., Feb. 26, 2026 – CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM

    PR Newswire ·